UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either

Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments in this sector [1] - The mission is to educate investors on conducting due diligence to avoid pitfalls in biotech investments [1] Group 2 - There is a potential for initiating a long position in URGN through stock or options purchases within the next 72 hours [2] - The article reflects the author's personal opinions and is not influenced by compensation from any company mentioned [2]